AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Cut by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. decreased its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 458,631 shares of the company's stock after selling 10,936 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in AstraZeneca were worth $30,050,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Trust Co. of Toledo NA OH raised its stake in AstraZeneca by 4.6% during the fourth quarter. Trust Co. of Toledo NA OH now owns 7,651 shares of the company's stock valued at $501,000 after buying an additional 337 shares in the last quarter. Moody National Bank Trust Division raised its stake in AstraZeneca by 20.0% during the fourth quarter. Moody National Bank Trust Division now owns 4,556 shares of the company's stock valued at $299,000 after buying an additional 758 shares in the last quarter. Miracle Mile Advisors LLC raised its stake in AstraZeneca by 445.7% during the fourth quarter. Miracle Mile Advisors LLC now owns 39,986 shares of the company's stock valued at $2,620,000 after buying an additional 32,659 shares in the last quarter. Tealwood Asset Management Inc. raised its stake in AstraZeneca by 0.8% during the fourth quarter. Tealwood Asset Management Inc. now owns 37,410 shares of the company's stock valued at $2,451,000 after buying an additional 290 shares in the last quarter. Finally, Wallace Advisory Group LLC acquired a new stake in AstraZeneca during the fourth quarter valued at approximately $171,000. Institutional investors and hedge funds own 20.35% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Morgan Stanley assumed coverage on AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Finally, BNP Paribas assumed coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $88.00.

AstraZeneca Stock Performance

AZN stock traded up $0.85 on Friday, reaching $68.81. The company's stock had a trading volume of 3,742,544 shares, compared to its average volume of 5,176,170. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68. The company has a market capitalization of $213.40 billion, a P/E ratio of 30.45, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The firm has a fifty day moving average of $70.46 and a two-hundred day moving average of $69.47. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The business had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same period in the prior year, the company posted $2.06 EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.